Orion Buske, CEO of Phenotypes, gave a presentation at the CORD Spring Conference in June 2022 about using patient phenotypes to drive genomic diagnostics for rare diseases. He explained that while genome sequencing can diagnose thousands of genetic conditions at once, clinicians need detailed phenotypic information to determine which are relevant to each patient's condition. PhenoTips is a digital platform that uses structured phenotypic data from sources like the Human Phenotype Ontology to help match patients to potential diagnoses, genes, and other related information to support precision medicine. It allows data sharing between hospitals, clinics, and research initiatives to help solve more rare disease cases.
The Human Phenotype Ontology (HPO) was developed to describe phenotypic abnormalities, aka, “deep phenotyping”, whereby symptoms and characteristic phenotypic findings (a phenotypic profile) are captured. The HPO has been utilized to great success for assisting computational phenotype comparison against known diseases, other patients, and model organisms to support diagnosis of rare disease patients. Clinicians and geneticists create phenotypic profiles based on clinical evaluation, but this is time consuming and can miss important phenotypic features. Patients are sometimes the best source of information about their symptoms that might otherwise be missed in a clinical encounter. However, HPO primarily use medical terminology, which can be difficult for patients and their families to understand. To make the HPO accessible to patients, we systematically added non-expert terminology (i.e., layperson terms) synonyms. Using semantic similarity, patient-recorded phenotypic profiles can be evaluated against those created clinically for undiagnosed patients to determine the improvement gained from the patient-driven phenotyping, as well as how much the patient phenotyping narrows the diagnosis. This patient-centric HPO can be utilized by all: in patient-centered rare disease websites, in patient community platforms and registries, or even to post one’s hard-to-diagnosed phenotypic profile on the Web.
The Application of the Human Phenotype Ontology mhaendel
Presented at the II International Summer School for Rare Disease and Orphan Drug Registries, September 15-19, 2014, Organized by the National Centre for Rare Diseases
Istituto Superiore di Sanità (ISS), Rome, Italy.
Note the extensive contribution by many consortium members and partners listed in the acknowledgements slide.
Patient-led deep phenotyping using a lay-friendly version of the Human Phenot...mhaendel
Presented at AMIA TBI CRI 2018.
Rare disease patients are expert in their medical history and these patients not only are some of the most engaged, but also they can themselves provision data for use in clinical evaluation. We therefore created a lay-person version of our clinical deep phenotyping instrument, the Human Phenotype Ontology. Here, we evaluate the diagnostic utility of this lay-HPO, and debut a new software tool for patient-led deep phenotyping.
Example OneDiscuss how new discoveries in genetics are contr.docxSANSKAR20
Example One
Discuss how new discoveries in genetics are contributing to our understanding of the HIV virus
and how some folks exposed to HIV have been able to escape developing AIDS.
The HIV virus daily infects 14,000 people, however some individuals’ odds of contracting the
virus are very low. Dr. Donald Mosier of the Script Institute was puzzled by this and launched a
genetic study to determine why certain individuals are resistant to the HIV virus. What Dr.
Mosier discovered was the resistant people inherited a deletion mutation that gave them
protection. Within the deletion mutation, the receptor CCR5, is excluded. This deleted section
of the CCR5 receptor functions as a lock, therefore people born with the mutation will not get
the HIV virus. Those individuals that are homozygous – have two copies of the same deletion
gene, are immune to the virus and are protected. Individuals that are heterozygous – have two
different genes – have some protection from HIV because their body have half the “locks.” Dr.
Mosier further studied populations and discovered the deleted mutation was higher in certain
parts of the world and among Caucasians.
Explain the genetic connection between phenotype and genotype discovered by Mendel in the
19th century.
Genetics helps to understand human diversity, not only in today’s world but in the past as well.
When studying genetics it is important to understand the relationship between phenotype and
genotype. A phenotype is defined as an observable physical characteristic whereas a genotype
is the set of specific genes an organism carries (Allen, Anton, Stanford 60). In the video lesson,
Anne Stone commented the phenotype can be impacted by the environment. For example, if
there is not sufficient food or there is disease, this can impact an individual’s height which is a
phenotype. Anthropologist Geneticist Joanna Mountain explained a phenotype can be
“measurements and anything we can describe about a person from appearance to metabolism.”
Utilizing the garden pea plant to conduct his experiment, Gregor Mendel was able to recognize
traits were passed on from parents to offspring. He knew traits were inherited but did not know
how this inheritance worked. Mendel’s Principles of Segregation which states in an organism,
alleles occurs in pairs and when gametes sex cells get produced, alleles separate so each
gamete contains one member of each pair. Further experiments by Mendel lead him to
conclude in a unit of inheritance, meaning offspring received receive genes from each parent.
Theses principles laid the foundation for future scientists to study inheritance.
Vocabulary
Phenotype – observable characteristics; expression of genetic instructions; something you can
measure
Genotype – genetic make-up of an individual; every person has a unique genotype made of
genes inherited from parents
Recessive – a masked trait or covered up
Dominant – mask recessive characteristics
P ...
The Human Phenotype Ontology (HPO) was developed to describe phenotypic abnormalities, aka, “deep phenotyping”, whereby symptoms and characteristic phenotypic findings (a phenotypic profile) are captured. The HPO has been utilized to great success for assisting computational phenotype comparison against known diseases, other patients, and model organisms to support diagnosis of rare disease patients. Clinicians and geneticists create phenotypic profiles based on clinical evaluation, but this is time consuming and can miss important phenotypic features. Patients are sometimes the best source of information about their symptoms that might otherwise be missed in a clinical encounter. However, HPO primarily use medical terminology, which can be difficult for patients and their families to understand. To make the HPO accessible to patients, we systematically added non-expert terminology (i.e., layperson terms) synonyms. Using semantic similarity, patient-recorded phenotypic profiles can be evaluated against those created clinically for undiagnosed patients to determine the improvement gained from the patient-driven phenotyping, as well as how much the patient phenotyping narrows the diagnosis. This patient-centric HPO can be utilized by all: in patient-centered rare disease websites, in patient community platforms and registries, or even to post one’s hard-to-diagnosed phenotypic profile on the Web.
The Application of the Human Phenotype Ontology mhaendel
Presented at the II International Summer School for Rare Disease and Orphan Drug Registries, September 15-19, 2014, Organized by the National Centre for Rare Diseases
Istituto Superiore di Sanità (ISS), Rome, Italy.
Note the extensive contribution by many consortium members and partners listed in the acknowledgements slide.
Patient-led deep phenotyping using a lay-friendly version of the Human Phenot...mhaendel
Presented at AMIA TBI CRI 2018.
Rare disease patients are expert in their medical history and these patients not only are some of the most engaged, but also they can themselves provision data for use in clinical evaluation. We therefore created a lay-person version of our clinical deep phenotyping instrument, the Human Phenotype Ontology. Here, we evaluate the diagnostic utility of this lay-HPO, and debut a new software tool for patient-led deep phenotyping.
Example OneDiscuss how new discoveries in genetics are contr.docxSANSKAR20
Example One
Discuss how new discoveries in genetics are contributing to our understanding of the HIV virus
and how some folks exposed to HIV have been able to escape developing AIDS.
The HIV virus daily infects 14,000 people, however some individuals’ odds of contracting the
virus are very low. Dr. Donald Mosier of the Script Institute was puzzled by this and launched a
genetic study to determine why certain individuals are resistant to the HIV virus. What Dr.
Mosier discovered was the resistant people inherited a deletion mutation that gave them
protection. Within the deletion mutation, the receptor CCR5, is excluded. This deleted section
of the CCR5 receptor functions as a lock, therefore people born with the mutation will not get
the HIV virus. Those individuals that are homozygous – have two copies of the same deletion
gene, are immune to the virus and are protected. Individuals that are heterozygous – have two
different genes – have some protection from HIV because their body have half the “locks.” Dr.
Mosier further studied populations and discovered the deleted mutation was higher in certain
parts of the world and among Caucasians.
Explain the genetic connection between phenotype and genotype discovered by Mendel in the
19th century.
Genetics helps to understand human diversity, not only in today’s world but in the past as well.
When studying genetics it is important to understand the relationship between phenotype and
genotype. A phenotype is defined as an observable physical characteristic whereas a genotype
is the set of specific genes an organism carries (Allen, Anton, Stanford 60). In the video lesson,
Anne Stone commented the phenotype can be impacted by the environment. For example, if
there is not sufficient food or there is disease, this can impact an individual’s height which is a
phenotype. Anthropologist Geneticist Joanna Mountain explained a phenotype can be
“measurements and anything we can describe about a person from appearance to metabolism.”
Utilizing the garden pea plant to conduct his experiment, Gregor Mendel was able to recognize
traits were passed on from parents to offspring. He knew traits were inherited but did not know
how this inheritance worked. Mendel’s Principles of Segregation which states in an organism,
alleles occurs in pairs and when gametes sex cells get produced, alleles separate so each
gamete contains one member of each pair. Further experiments by Mendel lead him to
conclude in a unit of inheritance, meaning offspring received receive genes from each parent.
Theses principles laid the foundation for future scientists to study inheritance.
Vocabulary
Phenotype – observable characteristics; expression of genetic instructions; something you can
measure
Genotype – genetic make-up of an individual; every person has a unique genotype made of
genes inherited from parents
Recessive – a masked trait or covered up
Dominant – mask recessive characteristics
P ...
Global Phenotypic Data Sharing Standards to Maximize Diagnostics and Mechanis...mhaendel
Presented at the IRDiRC 2017 conference in Paris, Feb 9th, 2017 (http://irdirc-conference.org/). This talk reviews use of the Human Phenotype Ontology for phenotype comparisons against other patients, known diseases, and animal models for diagnostic discovery. It also discusses the new Phenopackets Exchange mechanism for open phenotypic data sharing.
www.monarchinitiative.org
www.phenopackets.org
www.human-phenotype-ontology.org
Pleiotropy describes the genetic effect of a single gene on multiple phenotypic traits. The underlying mechanism is genes that code for a product that is either used by various cells or has a cascade-like signaling function that affects various targets.
Envisioning a world where everyone helps solve diseasemhaendel
Keynote presented at the Semantic Web for Life Sciences conference in Cambridge, UK, December 9th, 2015
http://www.swat4ls.org/
The talk focuses on the use of ontologies for data integration to support rare disease diagnostics, and how so very many people unbeknownst to the patient or even to the researchers creating the data are involved in a diagnosis.
On this webinar, we’ll hear from experts on the issue and invite an open conversation with stakeholders. We need discussion, shared questions and answers and a review of case studies, which is why we are hosting this session.
Panelist:
Neil Palmer, Principal Consultant, WN Palmer & Co. and former PMPRB staff
Michael Dietrich, Executive Director, Policy, Innovative Medicines Canada
Laurene Redding, Global Head, Strategic Pricing (ex-China), BeiGene
Durhane Wong-Rieger, President & CEO, CORD
Moderator: Bill Dempster, CEO, 3Sixty Public Affairs
Global Phenotypic Data Sharing Standards to Maximize Diagnostics and Mechanis...mhaendel
Presented at the IRDiRC 2017 conference in Paris, Feb 9th, 2017 (http://irdirc-conference.org/). This talk reviews use of the Human Phenotype Ontology for phenotype comparisons against other patients, known diseases, and animal models for diagnostic discovery. It also discusses the new Phenopackets Exchange mechanism for open phenotypic data sharing.
www.monarchinitiative.org
www.phenopackets.org
www.human-phenotype-ontology.org
Pleiotropy describes the genetic effect of a single gene on multiple phenotypic traits. The underlying mechanism is genes that code for a product that is either used by various cells or has a cascade-like signaling function that affects various targets.
Envisioning a world where everyone helps solve diseasemhaendel
Keynote presented at the Semantic Web for Life Sciences conference in Cambridge, UK, December 9th, 2015
http://www.swat4ls.org/
The talk focuses on the use of ontologies for data integration to support rare disease diagnostics, and how so very many people unbeknownst to the patient or even to the researchers creating the data are involved in a diagnosis.
On this webinar, we’ll hear from experts on the issue and invite an open conversation with stakeholders. We need discussion, shared questions and answers and a review of case studies, which is why we are hosting this session.
Panelist:
Neil Palmer, Principal Consultant, WN Palmer & Co. and former PMPRB staff
Michael Dietrich, Executive Director, Policy, Innovative Medicines Canada
Laurene Redding, Global Head, Strategic Pricing (ex-China), BeiGene
Durhane Wong-Rieger, President & CEO, CORD
Moderator: Bill Dempster, CEO, 3Sixty Public Affairs
CORD Rare Drug Conference: June 8-9, 2022
Registries and Real-World Data
INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty,
Monica Lamoureux, John Adams, Kim Angel
CORD Rare Drug Conference: June 8-9, 2022
Registries and Real-World Data
INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty,
Monica Lamoureux, John Adams, Kim Angel Opportunities and Challenges for Data Management
CORD Rare Drug Conference June 8-9, 2022
Global, International, and National Rare Disease Networks
Rare Disease Research Network and National Children’s Hospital - Marshall
Summar, Rare Disease Institute
CORD Rare Drug Conference: June 8-9, 2022
Global, International, and National Rare Disease Networks
WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
CORD Rare Drug Conference: June 8-9, 2022
Global, International, and National Rare Disease Networks
Canadian Network of Rare Disease Centres of Excellence - Paula Robeson, Children’s Healthcare Canada
CORD Rare Drug Conference: June 8 - 9, 2022
The Ottawa Pediatric Bone Health Research Group and The Canadian Consortium for Children’s Bone Health/Canadian Alliance for Rare Disorders of the Skeleton - Leanne Ward, CHEO
CORD Rare Drug Conference: June 8-9, 2022
What is status of Canadian access for RD drugs?
• Canada access and Rest of World - Alexandra Chambers, Novartis
• Canada access to essential rare disease drugs - Nigel Rawson
More from Canadian Organization for Rare Disorders (20)
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
2. How to provide a timely and accurate diagnosis?
Genome sequencing allows us to diagnose
1000s of genetic conditions with a single test
But it’s not really a single test, it’s thousands
or millions of them, all in parallel
We need to know which are relevant to the patient’s
condition
3. Labs frequently have to re-contact the ordering clinician to get more
detailed information
— GeneDx XomeDx
— Invitae Exome
The patient phenotype drives genomic diagnostics
4. phe·no·type /ˈfēnəˌtīp/
4
noun BIOLOGY
the set of observable characteristics
of an individual resulting from the
interaction of its genotype with the
environment.
What is a phenotype?
One eye
Short stature
Yellow skin
Sparse scalp hair
Conspicuously
happy disposition
5. Human Phenotype Ontology
13,000+ terms; 156,000+ associations to
7,000 rare diseases and 4,000 common diseases
eye disease
abnormal eye
morphology
coloboma
globe
abnormality
neurologic skeletal
...
abnormality
5
6. Structured data helps computers help us
6
diagnosis
phenotype–disease
genome analysis
phenotype–gene
matchmaking
phenotype–phenotype
8. Features to simplify deep phenotyping
Smart search Smart measurements
Microcephaly [HP:0000252]
[...] The patient presents with osseous maturation
and mild intellectual disability. Craniofacial
features include flat nasal bridge, large ears, long
philtrum, micrognathia, loose skin, and a triangular
face. [...]
Text mining
10. Hospitals
Portable data enables matchmaking
Research Clinics
National and International Initiatives
Matchmaking
Unsolved Cases
10
Check out the May 2022
special issue in Human
Mutation! [open access]
11. A huge thank you to our team, and
all the people and organizations
that have supported the project,
and the patients, providers and
researchers we are trying to benefit
through it.
Thank you.
orion@phenotips.com
11